Candida auris: A Quick Review on Identification, Current Treatments, and Challenges

Related Experiment Video

Updated: Jun 18, 2026

Clarifying and Imaging Candida albicans Biofilms
11:09

Clarifying and Imaging Candida albicans Biofilms

Published on: March 6, 2020

12.0K

Lucia Černáková1, Maryam Roudbary2, Susana Brás3

  • 1Department of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.

International Journal of Molecular Sciences
|April 30, 2021
PubMed

Insights

Candida auris infections are difficult to treat due to drug resistance and biofilm formation. This review covers identification challenges, current treatments, resistance mechanisms, and novel therapeutic strategies for this emerging fungal pathogen.

Area of Science:

  • Mycology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Candida auris is an emerging multidrug-resistant fungal pathogen causing outbreaks globally.
  • Treatment of C. auris infections is challenging due to limited therapeutic options and biofilm formation.
  • Misidentification of C. auris further complicates clinical management.

Purpose of the Study:

  • To review current challenges in C. auris identification.
  • To summarize available treatments and their associated resistance mechanisms.
  • To highlight novel and alternative therapeutic strategies against C. auris.

Main Methods:

  • Literature review of recent studies on Candida auris.
  • Analysis of identification methods, treatment outcomes, and resistance patterns.
  • Synthesis of information on emerging antifungal drugs and natural compounds.

Main Results:

  • C. auris exhibits high-level resistance to multiple antifungal drugs.
  • Biofilm formation significantly enhances C. auris resistance to standard therapies.
  • Accurate and rapid identification methods are crucial for effective C. auris management.

Conclusions:

  • Addressing C. auris requires improved diagnostics and a multifaceted therapeutic approach.
  • Development of new antifungal agents and strategies targeting biofilms is essential.
  • Continued research into resistance mechanisms will guide future treatment protocols.
Keywords:
Candida aurisantifungalbiofilminfectionnovel therapyresistance

More Related Videos

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients05:26

Author Spotlight: Oral Candida Diagnosis to Advance Clinical Treatment Regimen for pSS Patients

Published on: March 1, 2024

1.5K
Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

836

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Rapid Identification of Pathogens01:25

Rapid Identification of Pathogens

MALDI-TOF MS has transformed clinical microbiology by offering a rapid and reliable method for pathogen identification. The traditional approach to microbial identification typically involves time-consuming culture techniques and biochemical tests, which can delay the initiation of appropriate antimicrobial therapy. MALDI-TOF MS avoids these delays by using characteristic ribosomal protein mass patterns of microbial cells, enabling accurate species-level identification within minutes.Principle...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...